Kymera Investor Day Presentation Deck

Key Eligibility Criteria: R/R B-cell lymphoma Ⓡ ● KT-413: Clinical Study Design and Objectives Primary Objective: • To evaluate safety, PK/PD in Ⓡ > 2 prior systemic regimens Ineligible or refused CAR-T or ASCT ● Study Endpoints: Primary: Safety, tolerability, MTD/RP2D Secondary: PK, preliminary efficacy Exploratory: Target MYD88 mutant and MYD88 wild-type R/R DLBCL (IRAK4/Ikaros/Aiolos) knockdown and downstream effects in PBMC, and tumor KYMERA ©2021 KYMERA THERAPEUTICS, INC. DL1 Phase 1a Dose Escalation & MTD/RP2D Expansion DL2 DLX Protocol Amendment KT-413 + SOC Combo MTD/RP2D Expansion Protocol Amendment DL1-DLX DL1 DLx→ KYMERA R&D DAY - December 16th, 2021 MTD/RP2D Expansion MTD/RP2D Expansion Phase 1b Dose Expansion MyD88MT DLBCL ≥2 prior regimens MyD88WT DLBCL ≥2 prior regimens Waldenström's Macroglobulinemia Primary CNS Lymphoma Combination Expansion Combination Expansion PAGE 55

View entire presentation